Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Själander

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Evidence-Based Medicine|April 19, 2012
Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolismAnders Själander
Lakartidningen|June 26, 2008
[Auricular already exists!]Anders Själander
Lakartidningen|December 5, 2018
Sara Själander, Anders Själander
Lakartidningen|September 9, 2015
[NOAC in everyday clinical practice]Peter J Svensson, Anders Själander
Journal of Thrombosis and Thrombolysis|September 13, 2023
Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulantsJohan Lilja, Anders Själander, Sara Själander
Journal of Thrombosis and Thrombolysis|April 29, 2023
Direct oral anticoagulants: patient reported adherence and minor bleedingsAmina Hayat, Anders Själander, Jonas Wallvik
Journal of Thrombosis and Thrombolysis|November 3, 2020
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulantsNiklas Wallvik, Henrik Renlund, Anders Själander
Journal of Thrombosis and Thrombolysis|November 10, 2018
Predictors for INR-control in a well-managed warfarin treatment settingFredrik Björck, Hayder Kadhim, Anders Själander
Clinical Kidney Journal|October 18, 2024
Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulantsFrida Welander, Henrik Renlund, Anders Själander
Lakartidningen|October 27, 2010
[Guidelines for anticoagulation in patients with valve prosthesis. More supposition than scientific evidence]Anders Själander, Anders Jeppsson, Peter J Svensson
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Evidence-Based Medicine|April 19, 2012
Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolismAnders Själander
Lakartidningen|June 26, 2008
[Auricular already exists!]Anders Själander
Lakartidningen|December 5, 2018
Sara Själander, Anders Själander
Lakartidningen|September 9, 2015
[NOAC in everyday clinical practice]Peter J Svensson, Anders Själander
Journal of Thrombosis and Thrombolysis|September 13, 2023
Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulantsJohan Lilja, Anders Själander, Sara Själander
Journal of Thrombosis and Thrombolysis|April 29, 2023
Direct oral anticoagulants: patient reported adherence and minor bleedingsAmina Hayat, Anders Själander, Jonas Wallvik
Journal of Thrombosis and Thrombolysis|November 3, 2020
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulantsNiklas Wallvik, Henrik Renlund, Anders Själander
Journal of Thrombosis and Thrombolysis|November 10, 2018
Predictors for INR-control in a well-managed warfarin treatment settingFredrik Björck, Hayder Kadhim, Anders Själander
Clinical Kidney Journal|October 18, 2024
Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulantsFrida Welander, Henrik Renlund, Anders Själander
Lakartidningen|October 27, 2010
[Guidelines for anticoagulation in patients with valve prosthesis. More supposition than scientific evidence]Anders Själander, Anders Jeppsson, Peter J Svensson
Pageof 9